Movement Alert｜Eli Lilly Intraday Decline 3.34%, Morgan Stanley Target Hike Fails to Offset Shareholder Reduction and Sector Pullback

Market Focus

Oct 08

On October 8, Eli Lilly fell 3.34% in regular trading, trading at $1148.86/share, with Turnover of $5.09 billion.

Morgan Stanley and JPMorgan recently raised price targets and positive obesity pipeline data emerged, yet the stock retreated under high-level pressure.

Competition in the weight-loss drug space intensified as Novo Nordisk's CagriSema Phase 3 results showed superior weight loss versus low-dose Zepbound, raising concerns about market share erosion for Eli Lilly's products.

Eli Lilly is a global pharmaceutical leader focused on discovering, developing, manufacturing, and marketing human medicines across roughly 90 countries.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1153780180"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153780180\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153780180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153780180","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Eli Lilly Intraday Decline 3.34%, Morgan Stanley Target Hike Fails to Offset Shareholder Reduction and Sector Pullback","media":"Market Focus","content":"<p><p>On October 8, Eli Lilly fell 3.34% in regular trading, trading at $1148.86/share, with Turnover of $5.09 billion.</p><p>Morgan Stanley and JPMorgan recently raised price targets and positive obesity pipeline data emerged, yet the stock retreated under high-level pressure.</p><p>Competition in the weight-loss drug space intensified as Novo Nordisk's CagriSema Phase 3 results showed superior weight loss versus low-dose Zepbound, raising concerns about market share erosion for Eli Lilly's products.</p><p>Eli Lilly is a global pharmaceutical leader focused on discovering, developing, manufacturing, and marketing human medicines across roughly 90 countries.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Eli Lilly Intraday Decline 3.34%, Morgan Stanley Target Hike Fails to Offset Shareholder Reduction and Sector Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Eli Lilly Intraday Decline 3.34%, Morgan Stanley Target Hike Fails to Offset Shareholder Reduction and Sector Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-08 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 8, Eli Lilly fell 3.34% in regular trading, trading at $1148.86/share, with Turnover of $5.09 billion.</p><p>Morgan Stanley and JPMorgan recently raised price targets and positive obesity pipeline data emerged, yet the stock retreated under high-level pressure.</p><p>Competition in the weight-loss drug space intensified as Novo Nordisk's CagriSema Phase 3 results showed superior weight loss versus low-dose Zepbound, raising concerns about market share erosion for Eli Lilly's products.</p><p>Eli Lilly is a global pharmaceutical leader focused on discovering, developing, manufacturing, and marketing human medicines across roughly 90 countries.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1153780180","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153780180","pubTimestamp":1791468460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 8, Eli Lilly fell 3.34% in regular trading, trading at $1148.86/share, with Turnover of $5.09 billion.Morgan Stanley and JPMorgan recently raised price targets and positive obesity...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"走势警报|礼来盘中下跌3.34%，摩根士丹利上调目标未能抵消股东减持和板块回调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"On October 8, Eli Lilly fell 3.34% in regular trading, trading at $1148.86/share, with Turnover of $5.09 billion.Morgan Stanley and JPMorgan recently raised price targets and positive obesity pipeline data emerged, yet the stock retreated under high-level pressure.Competition in the weight-loss drug space intensified as Novo Nordisk's CagriSema Phase 3 results showed superior weight loss versus low-dose Zepbound, raising concerns about market share erosion for Eli Lilly's products.Eli Lilly is a global pharmaceutical leader focused on discovering, developing, manufacturing, and marketing human medicines across roughly 90 countries.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}